



# Senate

General Assembly

**File No. 328**

February Session, 2018

Senate Bill No. 208

*Senate, April 9, 2018*

The Committee on Insurance and Real Estate reported through SEN. LARSON of the 3rd Dist. and SEN. KELLY of the 21st Dist., Chairpersons of the Committee on the part of the Senate, that the bill ought to pass.

***AN ACT CONCERNING HEALTH INSURANCE COVERAGE OF ORALLY AND INTRAVENOUSLY ADMINISTERED MEDICATIONS.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective January 1, 2019*) Each insurance company,  
2 hospital service corporation, medical service corporation, health care  
3 center, fraternal benefit society or other entity that delivers, issues for  
4 delivery, renews, amends or continues in this state an individual  
5 health insurance policy providing coverage of the type specified in  
6 subdivision (1), (2), (4), (11), (12) or (16) of section 38a-469 of the  
7 general statutes that provides coverage for prescription drugs shall  
8 provide coverage for intravenously administered prescription drugs  
9 on a basis no less favorable than orally administered prescription  
10 drugs.

11 Sec. 2. (NEW) (*Effective January 1, 2019*) Each insurance company,  
12 hospital service corporation, medical service corporation, health care  
13 center, fraternal benefit society or other entity that delivers, issues for

14 delivery, renews, amends or continues in this state a group health  
15 insurance policy providing coverage of the type specified in  
16 subdivision (1), (2), (4), (11), (12) or (16) of section 38a-469 of the  
17 general statutes that provides coverage for prescription drugs shall  
18 provide coverage for intravenously administered prescription drugs  
19 on a basis no less favorable than orally administered prescription  
20 drugs.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>January 1, 2019</i>	New section
Sec. 2	<i>January 1, 2019</i>	New section

**INS**      *Joint Favorable*

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

---

***OFA Fiscal Note******State Impact:*** None***Municipal Impact:*** None***Explanation***

The bill is not anticipated to result in a fiscal impact to the state or municipalities as the bill will not impact current practice.

***The Out Years******State Impact:*** None***Municipal Impact:*** None

**OLR Bill Analysis****SB 208*****AN ACT CONCERNING HEALTH INSURANCE COVERAGE OF ORALLY AND INTRAVENOUSLY ADMINISTERED MEDICATIONS.*****SUMMARY**

This bill requires certain health insurance policies that cover prescription drugs to cover intravenously administered prescription drugs on a basis that is at least as favorable as orally administered prescription drugs.

The bill applies to each insurer, hospital or medical service corporation, HMO, or fraternal benefit society that delivers, issues, renews, amends, or continues in Connecticut individual or group health insurance policies that cover (1) basic hospital expenses; (2) basic medical-surgical expenses; (3) major medical expenses; (4) hospital or medical services, including those provided under an HMO plan; or (5) single service ancillary health coverage, including, prescription drug coverage. Because of the federal Employee Retirement Income Security Act (ERISA), state insurance benefit mandates do not apply to self-insured benefit plans.

EFFECTIVE DATE: January 1, 2019

**COMMITTEE ACTION**

Insurance and Real Estate Committee

Joint Favorable

Yea 17 Nay 4 (03/20/2018)